在复发/难治性B细胞急性淋巴细胞白血病成人中，对抗抗原的抗体和细胞疗法进行顺序排列。
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
发表日期：2023 Jan 24
作者：
Ibrahim Aldoss, Bijal D Shah, Jae H Park, Lori Muffly, Aaron C Logan, Patrick Brown, Wendy Stock, Elias J Jabbour
来源：
AMERICAN JOURNAL OF HEMATOLOGY
摘要：
针对B细胞急性淋巴细胞白血病（B-ALL）的CD19或CD22靶向疗法近期获批，已经改变了复发/难治（r/r）病情的治疗方式。成年人r/r B-ALL通常有多种治疗选择，但目前尚无直接比较这些药物的研究，医生必须决定选择哪种疗法。每种疗法作为单一剂型均具有显著的活性，但在特定情况下存在局限性，最佳选择因人而异。这些疗法可以互补使用，顺序或同时使用。在此，我们回顾了r/r B-ALL抗原靶向治疗的现状，并讨论了其使用的考虑因素。© 2023 Wiley Periodicals LLC.
The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.© 2023 Wiley Periodicals LLC.